Madrigal Solidifies Presumed NASH Lead With 52-Week Data

 
• By Joseph Haas
Madrigal office
Madrigal continues to build a solid data rationale behind resmetirom • Source: Madrigal Pharmaceuticals

More from Clinical Trials

More from R&D